OrbiMed Israel BioFund GP Limited Partnership 13D and 13G filings for NOVUS THERAPEUTICS INC:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-01-05 4:38 pm Unchanged |
2020-12-22 | 13D | NOVUS THERAPEUTICS INC NVUS |
OrbiMed Israel BioFund GP Limited Partnership | 73,650 0.500% |
0 (Unchanged) |
Filing |
| 2020-12-04 5:12 pm Sale |
2020-12-02 | 13D | NOVUS THERAPEUTICS INC NVUS |
OrbiMed Israel BioFund GP Limited Partnership | 73,650 5.100% |
-103,200 (-58.35%) |
Filing |
| 2020-11-20 4:39 pm Unchanged |
2020-11-16 | 13D | NOVUS THERAPEUTICS INC NVUS |
OrbiMed Israel BioFund GP Limited Partnership | 176,850 12.400% |
0 (Unchanged) |
Filing |
| 2020-10-13 9:20 pm Purchase |
2020-10-05 | 13D | NOVUS THERAPEUTICS INC NVUS |
OrbiMed Israel BioFund GP Limited Partnership | 176,850 14.100% |
176,850 (New Position) |
Filing |